The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences,
The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin.
대표청구항▼
1. A method of treating anemia in a human subject in need over a sustained time period comprising the steps of: (a) providing at least one autologous erythropoietin secreting genetically modified dermal micro-organ that comprises a helper-dependent adenovirus vector comprising the nucleic acid seque
1. A method of treating anemia in a human subject in need over a sustained time period comprising the steps of: (a) providing at least one autologous erythropoietin secreting genetically modified dermal micro-organ that comprises a helper-dependent adenovirus vector comprising the nucleic acid sequence encoding erythropoietin operably linked to one or more regulatory sequences, wherein said nucleic acid comprises SEQ ID NO: 11,(b) determining the erythropoietin secretion levels of the at least one genetically modified dermal micro-organ in step (a) in vitro,(c) implanting the autologous genetically modified dermal micro-organ of step (b) in said human subject at an effective dosage at a site selected from the group consisting of subcutaneously, subdermally and intradermally,(d) measuring hemoglobin levels in the blood of said human subject from step (c); and(e) maintaining hemoglobin levels in said human subject at 9-11 g/dl in at least 50% of the measurements for at least one month, thereby treating anemia in a human subject. 2. The method of claim 1, wherein the autologous genetically modified dermal micro-organ to be implanted provides said an effective dosage of 18-150 U erythropoietin/Kg body weight of said subject/day, as determined by in vitro secretion of erythropoietin from the genetically modified micro-organ. 3. The method of claim 2, wherein the autologous genetically modified dermal micro-organ to be implanted provides said an effective dosage of 18-30 U erythropoietin/Kg body weight of said subject/day, as determined by in vitro secretion of erythropoietin from the genetically modified micro-organ. 4. The method of claim 2, wherein the autologous genetically modified dermal micro-organ to be implanted provides said an effective dosage of 30-50 U erythropoietin/Kg body weight of said subject/day, as determined by in vitro secretion of erythropoietin from the genetically modified micro-organ. 5. The method of claim 2, wherein the autologous genetically modified dermal micro-organ to be implanted provides said an effective dosage of 50-65 U erythropoietin/Kg body weight of said subject/day, as determined by in vitro secretion of erythropoietin from the genetically modified micro-organ. 6. The method of claim 2, wherein said effective dosage is determined based on: a. said subject′s weight;b. said subject′s historical hemoglobin levels; andc. the average amount of erythropoientin administered to said subject in the one month prior said implanting step. 7. The method of claim 1, wherein said measured hemoglobin levels are 9-11 g/dl in at least 50% of the measurements for at least six months. 8. The method of claim 1, further comprising a step of implanting at a later date to said human subject, at least one additional autologous erythropoietin secreting genetically modified dermal micro-organ that comprises a helper-dependent adenovirus vector comprising the nucleic acid sequence encoding erythropoietin operably linked to one or more regulatory sequences, wherein said nucleic acid comprises SEQ ID NO: 11. 9. The method of claim 1, further comprising a step of maintaining said at least one genetically modified dermal micro-organ in vitro for at least 9 days, prior to said implantation step. 10. The method of claim 1, wherein said subject is selected from a group consisting of: a. a subject suffering from: renal failure, chronic renal failure, chemotherapy induced anemia, anemia as a result of HIV treatments, microangiopathic haemolytic anemia, anemia as a result of prematurity, an inflammatory condition including rheumatoid arthritis, an infection, anemia associated with cancers including multiple myeloma and non-Hodgkin lymphoma, hematopoietic stem cell disorders, sickle cell anemia or thalassemia; andb. a subject in need of accelerated erythroid repopulation after bone marrow transplantation; or any combination thereof. 11. The method of claim 10, wherein said subject suffering from chronic renal failure is suffering from chronic kidney disease (CKD) or end stage renal disease (ESRD). 12. A method of increasing or maintaining physiological hemoglobin levels in a human subject in need over a sustained time period comprising the steps of: (a) providing at least one autologous erythropoietin secreting genetically modified dermal micro-organ that comprises a helper-dependent adenovirus vector comprising the nucleic acid sequence encoding erythropoietin operably linked to one or more regulatory sequences, wherein said nucleic acid comprises SEQ ID NO: 11,(b) determining the erythropoietin secretion levels of the at least one genetically modified dermal micro-organ in step (a) in vitro,(c) implanting the autologous genetically modified dermal micro-organ of step (b) in said human subject at an effective dosage at a site selected from the group consisting of subcutaneously, subdermally and intradermally,(d) measuring hemoglobin levels in the blood of said human subject from step (c); and(e) maintaining hemoglobin levels in said human subject at 9-11 g/dl in at least 50% of the measurements for at least one month, thereby increasing or maintaining physiological hemoglobin levels in a human subject. 13. The method of claim 12, wherein the autologous genetically modified dermal micro-organ to be implanted provides said an effective dosage of 18-150 U erythropoietin/Kg body weight of said subject/day, as determined by in vitro secretion of erythropoietin from the genetically modified micro-organ. 14. The method of claim 13, wherein the autologous genetically modified dermal micro-organ to be implanted provides said an effective dosage of 18-30 U erythropoietin/Kg body weight of said subject/day, as determined by in vitro secretion of erythropoietin from the genetically modified micro-organ. 15. The method of claim 13, wherein the autologous genetically modified dermal micro-organ to be implanted provides said an effective dosage of 30-50 U erythropoietin/Kg body weight of said subject/day, as determined by in vitro secretion of erythropoietin from the genetically modified micro-organ. 16. The method of claim 13, wherein the autologous genetically modified dermal micro-organ to be implanted provides said an effective dosage of 50-65 U erythropoietin/Kg body weight of said subject/day, as determined by in vitro secretion of erythropoietin from the genetically modified micro-organ.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (67)
Leder Philip (Chestnut Hill MA) Muller William J. (Cambridge MA), Animal model for benign prostatic disease.
Sittinger Michael,DEX ; Schultz Olaf,DEX ; Burmester Gerd R.,DEX ; Haupl Thomas E. M.,DEX, Artificial tissues, methods for the production and the use thereof.
Beck Anton K. (Wellesley MA) Withy Raymond M. (Framingham MA) Zabrecky James R. (Framingham MA) Masiello Nicholas C. (Milford MA), Cell encoding recombinant human erythropoietin.
Capecchi Mario R. (Salt Lake City UT) Thomas Kirk R. (Salt Lake City UT), Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and.
Ohtsuka Eiko (Sappro JPX) Inoue Hideo (Sappro JPX) Morisawa Hirokazu (Kawasaki JPX) Shibahara Susumu (Kawasaki JPX) Mukai Sachiko (Kawasaki JPX) Nishihara Tohru (Kurashiki JPX), Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and st.
Sabel Bernhard A. (Munich MA DEX) Freese Andrew (Jamaica Plain MA) Saltzman William M. (Somerville MA), Controlled drug delivery system for treatment of neural disorders.
Weinshank Richard L. (New York NY) Branchek Theresa (Teaneck NJ) Hartig Paul R. (Mahwah NJ), DNA encoding a human 5-HT1F receptor, vectors, and host cells.
Motamedi Haideh (Westfield NJ) Shafiee Ali (Westfield NJ), Expression cassettes useful in construction of integrative and replicative expression vectors for Streptomyces.
Aebischer Patrick (Providence RI) Winn Shelley R. (Providence RI) Galletti Pierre M. (Providence RI), In vivo delivery of neurotransmitters by implanted, encapsulated cells.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Walder Joseph A. (Iowa City IA) Walder Roxanne Y. (Iowa City IA) Eder Paul S. (Iowa City IA) Dagle John M. (Iowa City IA), Methods for blocking the expression of specifically targeted genes.
Dionne Keith E. ; Emerich Dwaine F. ; Hoffman Diane ; Sanberg Paul R. ; Christenson Lisa ; Hegre Orion D. ; Scharp David W. ; Lacy Paul E. ; Aebischer Patrick,CHX ; Vasconcellos Alfred V. ; Lysaght M, Methods for treatment or prevention of neurodegenerative conditions using immunoisolatory implantable vehicles with a bi.
Mullis Kary B. (Kensington CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or-cloning nucleic acid sequences.
Krimpenfort Paulus J. A. (Amsterdam NLX) Berns Antonius J. M. (Spaarndam NLX), Transgenic mice depleted in mature T-cells and methods for making transgenic mice.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.